Time filter

Source Type

Houston, United States

Sahni L.C.,Immunization Project | Banes M.R.,Ambulatory Services | Boom J.A.,Baylor College of Medicine
Academic Pediatrics | Year: 2016

Objective: Immunization reminder/recall is widely recommended as an effective strategy for increasing vaccination rates. We examined the revenue generated from well-child visits scheduled as a result of reminder/recall activities implemented in a multipractice pediatric organization. Methods: Patients aged 19 to 35 months who were due or overdue for vaccines were identified from participating practices and assigned to either standard or enhanced reminder/recall activities. Participants who received standard reminder/recall were observed for the 6-week study period, and the number of appointments in which vaccines were administered was tracked. Participants who received enhanced reminder/recall were contacted up to 3 times and received a letter followed by up to 2 phone calls. Financial information associated with appointments scheduled during the study period was obtained, and revenue was calculated for each dose of vaccine administered. Reminder/recall costs were calculated and overall revenue generated was calculated. Results: We identified 3916 children who were potentially due or overdue for immunizations. After review and manual uploading of missing historical vaccines, a total of 1892 participants received the reminder/recall initiative; 942 received standard reminder/recall, and 950 received enhanced reminder/recall. One hundred eighty-two (19%) standard and 277 (29%) enhanced reminder/recall participants scheduled an appointment by the end of the study period (P < .001). After subtracting the cost of reminder/recall activities, an additional $20,066 and $20,235 were generated by standard and enhanced reminder/recall, respectively. Conclusions: We show that conducting reminder/recall is at a minimum financially neutral, and might increase revenue generated by vaccine administration. © 2016 Academic Pediatric Association.

Boom J.A.,Immunization Project | Boom J.A.,Center for Vaccine Awareness and Research | Boom J.A.,Baylor College of Medicine | Sahni L.C.,Immunization Action Plan Coordinator | And 3 more authors.
Journal of Public Health Management and Practice | Year: 2010

Immunization information systems (IISs) are confidential, population-based systems that contain immunization data for children, and, in some cases, adults, within a geographic area. There are generally two models for participation in an IIS, termed voluntary exclusion or "opt-out" and voluntary inclusion or "opt-in." Using the Texas opt-in consent system and statewide IIS (ImmTrac), we describe the costs associated with obtaining opt-in consent in hospitals as part of the birth registration process and in provider offices for children without prior consent. We also estimate the costs associated with a hypothetical opt-out system. Between October 2006 and August 2007, project staff conducted on-site time studies for patients in 8 birthing hospitals (n = 281), 16 provider offices (n = 131), and ImmTrac state offices in Austin, Texas (n = 100). Total costs per child and costs per year were estimated using a time-and-motion study in which the time associated with discussing ImmTrac and obtaining ImmTrac consent was measured. The annual costs associated with obtaining consent for Texas' opt-in IIS are estimated at $1 389 804.61. The average per child cost associated with ImmTrac consent completed at birth is $2.00, whereas the per child cost for consent completed in provider offices is $2.64. The annual costs of operating an alternative, opt-out system are estimated at $110 714.03, or $0.29 per child. This cost analysis demonstrated that the proposed opt-out costs were substantially less than the actual opt-in model currently utilized. Changing to an opt-out system could redirect limited healthcare funding to more critical areas such as vaccine purchasing and administration. Copyright © 2010 Wolters Kluwer Health.

Sahni L.C.,Immunization Project | Tate J.E.,Centers for Disease Control and Prevention | Payne D.C.,Centers for Disease Control and Prevention | Parashar U.D.,Centers for Disease Control and Prevention | And 2 more authors.
Pediatrics | Year: 2015

BACKGROUND: Rotavirus vaccines were introduced in the United States in 2006. Full-series coverage is lower than for other vaccines, and disease continues to occur. We examined variation in vaccine coverage among provider locations and correlated coverage with the detection of rotavirus in children who sought treatment of severe acute gastroenteritis (AGE). METHODS: Vaccine records of children enrolled in an AGE surveillance program were obtained and children were grouped by the location that administered each child's 2-month vaccines. Cases were children with laboratory-confirmed rotavirus AGE; controls were children with rotavirus-negative AGE or acute respiratory infection. Location-level coverage was calculated using ≥1 dose rotavirus vaccine coverage among controls and classified as low (,40%), medium (≥40% to <80%), or high (≥80%). Rotavirus detection rates among patients with AGE were calculated by vaccine coverage category. RESULTS: Of controls, 80.4% (n = 1123 of 1396) received ≥1 dose of rotavirus vaccine from 68 locations. Four (5.9%) locations, including a NICU, were low coverage, 22 (32.3%) were medium coverage, and 42 (61.8%) were high coverage. In low-coverage locations, 31.4% of patients with AGE were rotavirus-positive compared with 13.1% and 9.6% in medium- and high-coverage locations, respectively. Patients with AGE from low-coverage locations had 3.3 (95% confidence interval 2.4-4.4) times the detection rate of rotavirus than patients with AGE from high vaccine coverage locations. CONCLUSIONS: We observed the highest detection of rotavirus disease among locations with low rotavirus vaccine coverage, suggesting that ongoing disease transmission is related to failure to vaccinate. Educational efforts focusing on timely rotavirus vaccine administration to age-eligible infants are needed. Copyright © 2015 by the American Academy of Pediatrics

Wang D.,University of Texas at Austin | Cunningham R.,Immunization Project | Boom J.,Immunization Project | Amith M.,University of Texas Health Science Center at Houston | Tao C.,University of Texas Health Science Center at Houston
Studies in Health Technology and Informatics | Year: 2016

Human papillomavirus is a widespread sexually transmitted infection that can be prevented with vaccination. However, HPV vaccination rates in the United States are disappointingly low. This paper will introduce a patient oriented web ontology intended to provide an interactive way to educate patients about HPV and the HPV vaccine that will to empower patients to make the right vaccination decision. The information gathered for this initial draft of the ontology was primarily taken from the Centers for Disease Control and Prevention's Vaccine Information Statements. The ontology currently consists of 160 triples, 141 classes, 52 properties and 55 individuals. For future iterations, we aim to incorporate more information as well as obtain subject matter expert feedback to improve the overall quality of the ontology. © 2016 IMIA and IOS Press.

Goin-Kochel R.P.,Baylor College of Medicine | Goin-Kochel R.P.,Autism Center | Mire S.S.,University of Houston | Dempsey A.G.,University of Houston | And 6 more authors.
Vaccine | Year: 2016

A contentious theory espoused by some parents is that regressive-onset of autism spectrum disorder (ASD) is triggered by vaccines. If this were true, then vaccine receipt should be higher in children with regressive-onset ASD compared with other patterns of onset. Parental report of rate of receipt for six vaccines (DPT/DTaP, HepB, Hib, polio, MMR, varicella) was examined in children with ASD (N = 2755) who were categorized by pattern of ASD onset (early onset, plateau, delay-plus-regression, regression). All pairwise comparisons were significantly equivalent within a 10% margin for all vaccines except varicella, for which the delay-plus-regression group had lower rates of receipt (81%) than the early-onset (87%) and regression (87%) groups. Findings do not support a connection between regressive-onset ASD and vaccines in this cohort. © 2016 Elsevier Ltd.

Discover hidden collaborations